Tracer library / [161Tb]Tb-BL02
[161Tb]Tb-BL02
Also written as [Tb-161]Tb-BL02
- Radionuclide
- Tb-161 t½ 9907.2 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- CXCR4-targeting radioconjugate derived from LY2510924 (peptide-based CXCR4 antagonist)
- Target / mechanism
- CXCR4 (chemokine receptor 4) antagonist-based targeting PMID 42653659
- Clinical application
- Preclinical theranostic radioconjugate for CXCR4-targeted therapy of hematologic malignancies PMID 42653659
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | custom manifold | SPE | >99% | >99% | BL02 Pepmic Co., Ltd., Suzhou, China | 42653659 2026 Pharmaceuticals (Basel) [177Lu]Lu-BL02 and [161Tb]Tb-BL02 were manually labeled with radiochemical conversions (RCC) exceeding 99% for both tracers on iTLC. - were manually labeled with radiochemical conversions (RCC) exceeding 99% for both tracers on iTLC |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- Pepmic Co., Ltd.
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [161Tb]Tb-BL02, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42653659. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 42653659: 'In vivo biodistribution and pharmacokinetics were evaluated in MM.1S xenograft mouse models, supported by longitudinal SPECT imaging.'. | Stage 28: added indication(s) onc-myeloma from consolidated missing-rubric review.